However, data supporting the positive effects of mineralocorticoid receptor antagonists (MRA) as a renin-angiotensin-aldosterone system-targeting therapy are limited for cardiovascular outcomes in patients with CKD and AMI because these patients are often excluded from most clinical trials on which guidelines are based (Coca et al., 2006). This evidence concerns the gene NR3C2 and chronic kidney disease.